Jonathan A. Ledermann
University College London (UCL) Cancer Institute
UCL & UCL Hospitals Comprehensive Biomedical Research Centre
90 Tottenham Court Rd.
London W1T 4TJ
United Kingdom
Name/email consistency: high
- Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C., Meier, W., Shapira-Frommer, R., Safra, T., Matei, D., Macpherson, E., Watkins, C., Carmichael, J., Matulonis, U. N. Engl. J. Med. (2012)
- Randomized Phase II Placebo-Controlled Trial of Maintenance Therapy Using the Oral Triple Angiokinase Inhibitor BIBF 1120 After Chemotherapy for Relapsed Ovarian Cancer. Ledermann, J.A., Hackshaw, A., Kaye, S., Jayson, G., Gabra, H., McNeish, I., Earl, H., Perren, T., Gore, M., Persic, M., Adams, M., James, L., Temple, G., Merger, M., Rustin, G. J. Clin. Oncol. (2011)
- Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer. Ledermann, J.A., Gabra, H., Jayson, G.C., Spanswick, V.J., Rustin, G.J., Jitlal, M., James, L.E., Hartley, J.A. Clin. Cancer Res. (2010)
- Targeted trials in ovarian cancer. Ledermann, J.A., Raja, F.A. Gynecol. Oncol. (2010)
- Lessons learned from a decade of clinical trials of high-dose chemotherapy in ovarian cancer. Ledermann, J.A. Int. J. Gynecol. Cancer (2008)
- How should we manage patients with "platinum-sensitive" recurrent ovarian cancer?. Ledermann, J.A., Wheeler, S. Cancer Invest. (2004)